Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials

Inflammatory Bowel Disease

Endoscopic response to subcutaneous infliximab by disease location: A post hoc analysis of the LIBERTY-CD study

Clin Gastroenterol Hepatol

Sands BE, Schreiber S, Dubinsky MC, D'Haens G, Abraham BP, Regueiro M, Danese S, Park H, Kim DH, Lee YN, Hanauer SB, Colombel JF

doi: 10.1016/j.cgh.2025.11.017

Gastrointestinal Cancer

Long-term oncological outcomes following algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection: a post-hoc analysis of a nationwide, stepped-wedge cluster-randomised trial

Lancet Gastroenterol Hepatol

Schouten TJ, Prinsze KJ, Henry AC, Daamen LA, Besselink MG, Bonsing BA, Bosscha K, Busch OR, Cirkel GA, van Dam RM, van Eijck CH, Festen S, Groot Koerkamp B, van der Harst E, de Hingh IHJT, Kazemier G, Liem MSL, de Meijer VE, Sven D Mieog J, Patijn GA, Roos D, Schreinemakers JMJ, Stommel MWJ, Wit F, van Werkhoven CH, Molenaar IQ, Smits FJ, van Santvoort HC, Dutch Pancreatic Cancer Group

doi: 10.1016/S2468-1253(25)00367-X

Gastrointestinal Cancer

Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial

JAMA Oncol

Reiss KA, Xia M, Akamandisa M, D'Andrea K, Wubbenhorst B, Lord CJ, Pettitt SJ, Tutt ANJ, Brown TJ, O'Hara MH, Schneider C, Teitelbaum U, Hannan Z, Hood R, Tondon R, Vonderheide RH, Domchek SM, Nathanson KL

doi: 10.1001/jamaoncol.2026.0870

Inflammatory Bowel Disease

Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResource

Inflamm Bowel Dis

Yan K, Vuyyuru SK, Taylor A, Figueredo G, Raine T, Sanon M, Naessens D, Munje C, Moran GW

doi: 10.1093/ibd/izaf276

Hepatitis

Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B - follow-up from the RETRACT-B cohort

J Hepatol

Dongelmans E, Hirode G, van Bӧmmel F, Jeng WJ, Chien RN, Chen CH, Kilany M, Su TH, Kao JH, Seto WK, Liang LY, Reikvam DH, Holmberg M, Furquim d'Almeida A, Papatheodoridi M, Maasoumy B, Hansen B, Post R, Pocurull A, Terrault N, Ghany M, Johannessen A, Lok A, Vanwolleghem T, Lens S, Cornberg M, Yuen MF, Wong G, Sonneveld M, Papatheodoridis G, Berg T, Hsu YC, Feld J, Janssen H, RETRACT-B study group

doi: 10.1016/j.jhep.2026.03.030

Gastrointestinal Cancer

Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial

J Clin Oncol

Tang Y, Zhou HT, Xu TZ, Li N, Jiang LM, Jiang J, Lu NN, Li S, Chen SL, Ma HY, Cai Y, Li YH, Zhu Y, He MY, Wang X, Liu K, Zhang HY, Wang J, Zhao T, Li GF, Yang JL, Zhang K, Wang WL, Xiao WW, Chi Y, Yang L, Zhou AP, Zou SM, Fang H, Wang SL, Zhang HZ, Wang XS, Wei LC, Liu SX, Gao YH, Li YX, Hu C, Jin J

doi: 10.1200/JCO-25-02387

Inflammatory Bowel Disease

Efficacy and safety of ulcerative colitis therapies do not differ by age: A post hoc analysis of randomized controlled trials

Inflamm Bowel Dis

Wong ECL, Marshall JK, Ma C, Jairath V, Reinisch W, Narula N

doi: 10.1093/ibd/izag054

Gastrointestinal Cancer

Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up

Adv Ther

Cruz-Correa M, Oh DY, Kato K, Tabernero J, Bai Y, Shi J, Lee KW, Hirano H, Spigel D, Wyrwicz L, Pazo Cid R, Cubillo Gracián A, Xu Y, Sheng T, Yang S, Xu RH, Moehler M

doi: 10.1007/s12325-025-03415-0

ColonoscopyGastrointestinal Cancer

Colonoscopy versus biennial FIT screening: a post hoc sustained-strategy analysis of the COLONPREV Trial

Gut

Castells A, Quintero E, Chen H, Bujanda L, Castán-Cameo S, Cubiella J, Díaz-Tasende J, Lanas Á, Ono A, Serra-Burriel M, COLONPREV Study Investigators

doi: 10.1136/gutjnl-2026-338896

Related content

Endoscopic response to subcutaneous infliximab by disease location: A post hoc analysis of the LIBERTY-CD study

Long-term oncological outcomes following algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection: a post-hoc analysis of a nationwide, stepped-wedge cluster-randomised trial

Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial

Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResource

Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B - follow-up from the RETRACT-B cohort

Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial

Efficacy and safety of ulcerative colitis therapies do not differ by age: A post hoc analysis of randomized controlled trials

Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up

Colonoscopy versus biennial FIT screening: a post hoc sustained-strategy analysis of the COLONPREV Trial